(Q30351493)

20 June 2017

2 references

22 October 2022

Obstacles and advances in SARS vaccine development. (English)

1 reference

20 June 2017

0 references

Deborah R Taylor

1

1 reference

20 June 2017

language of work or name

English

0 references

publication date

12 September 2005

1 reference

20 June 2017

13 February 2006

1 reference

22 October 2022

2 references

20 June 2017

22 October 2022

24

1 reference

20 June 2017

issue

7

1 reference

20 June 2017

page(s)

863-871

1 reference

Critically ill patients with severe acute respiratory syndrome

20 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

A novel coronavirus associated with severe acute respiratory syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

SARS--beginning to understand a new virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Severe acute respiratory syndrome coronavirus phylogeny: toward consensus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Identification of a new human coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Lung pathology of fatal severe acute respiratory syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Expression of lymphocytes and lymphocyte subsets in patients with severe acute respiratory syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Dissection study on the severe acute respiratory syndrome 3C-like protease reveals the critical role of the extra domain in dimerization of the enzyme: defining the extra domain as a new target for design of highly specific protease inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

SARS in newborns and children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Role of China in the Quest To Define and Control Severe Acute Respiratory Syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Mice susceptible to SARS coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Virology: SARS virus infection of cats and ferrets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Aetiology: Koch's postulates fulfilled for SARS virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Macaque model for severe acute respiratory syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Protection of chickens after live and inactivated virus vaccination against challenge with nephropathogenic infectious bronchitis virus PA/Wolgemuth/98.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Safety and efficacy of a modified-live canine coronavirus vaccine in dogs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Inactivated hepatitis A vaccine: active and passive immunoprophylaxis in chimpanzees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Live attenuated varicella vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Highly infectious SARS-CoV pseudotyped virus reveals the cell tropism and its correlation with receptor expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Genetically engineered vaccines: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Developing new smallpox vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Current status and future trends in vaccine regulation--USA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

SARS-associated coronavirus quasispecies in individual patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

SARS associated coronavirus has a recombinant polymerase and coronaviruses have a history of host-shifting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Mosaic evolution of the severe acute respiratory syndrome coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Antibody-Dependent Enhancement of Virus Infection and Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

The role of IgG subclass of mouse monoclonal antibodies in antibody-dependent enhancement of feline infectious peritonitis virus infection of feline macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Antibody-dependent enhancement of feline infectious peritonitis virus infection in feline alveolar macrophages and human monocyte cell line U937 by serum of cats experimentally or naturally infected with feline coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Immune responses in Balb/c mice induced by a candidate SARS-CoV inactivated vaccine prepared from F69 strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Assembly of human severe acute respiratory syndrome coronavirus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Effects of a SARS-associated coronavirus vaccine in monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

DNA vaccine of SARS-Cov S gene induces antibody response in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

SARS CTL vaccine candidates; HLA supertype-, genome-wide scanning and biochemical validation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

Localization of antigenic sites of the S glycoprotein of feline infectious peritonitis virus involved in neutralization and antibody-dependent enhancement.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.102

inferred from DOI database lookup

7 January 2021

based on heuristic

SARS coronavirus-infected cells in lung detected by new in situ hybridization technique

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16191455

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16191455

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2005.08.102

1 reference

20 June 2017

0 references

1 reference